Finance Watch: VC Enthusiasm For Biopharma Continues As 5AM Ventures Raises $750m

Venture capital investment in private biopharmaceutical companies seems to have kept up a strong pace in 2022 relative to investment in publicly traded drug developers, which have been challenged to raise money this year while their stock prices largely have been in decline. Several private companies have raised significant VC funding rounds and many venture firms have raised large new funds – including, most recently, 5AM Ventures with $750m across two funds.

While initial public offerings have been limited in 2022 compared with the last two years, which both produced record-breaking IPO totals, the need for big pharma to fill its pipelines with new drug candidates has not decreased. (Also see "Finance Watch: Biopharma IPO Market Silence Continues In The US" - Scrip, 15 March, 2022